1933 - 1999

Odette Cancer Centre – A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.

It seems we can’t find what you’re looking for. Perhaps searching can help.